Lupin To Present Cancer Drug Data at ASCO 2025

27 May 2025 CW Team

Global pharmaceutical firm Lupin Limited will present results from its Phase 1a clinical trial of LNP7457—a novel PRMT5 inhibitor—at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from 30 May to 3 June 2025. The data will be showcased during the Developmental Therapeutics—Molecularly Targeted Agents and Tumour Biology session on 2 June, between 1:30 pm and 4:30 pm (CDT), at Poster Board #422.

LNP7457 is a SAM-competitive PRMT5 inhibitor being developed for monotherapy in patients with advanced or metastatic solid tumours. According to trial findings, the drug has shown a favourable safety and tolerability profile, with pharmacokinetic/pharmacodynamic (PK/PD) data supporting further development. Food intake was found to have no impact on drug metabolism.

The maximum tolerated dose and the recommended Phase 2 dose were established based on cumulative safety, PK/PD, and efficacy data, and are consistent with preclinical models and existing safety profiles of PRMT5 inhibitors.

Vinita Gupta, CEO of Lupin, commented, “We are pleased to share encouraging data from our Phase I trial. LNP7457 represents a novel epigenetic therapeutic with significant promise, and reinforces our commitment to advancing innovative treatments for cancers with limited options.”

Lupin has already commenced its Phase 1b trial in India and aims to further evaluate LNP7457 for various oncology indications where unmet clinical needs persist.

Presentation Details:

4. Date: 2 June 2025

5. Time: 1:30–4:30 pm CDT

6. Location: Hall A, McCormick Place, Chicago

7. Abstract No.: 3107 | Poster Board No.: 422

8. Trial Registration: CTRI/2023/07/054753

9. DOI: 10.1200/JCO.2025.43.16_suppl.3107

Lupin’s participation at ASCO underscores its focus on precision oncology and its ambitions in the field of targeted cancer therapies.

Infrastructure Transport

11 May 2026

RAHSTA 2026 to Host Certified Highway Construction Masterclass

RAHSTA 2026 will organise the Certified Highway Construction Masterclass, a specialised two-day corporate training programme for highway construction professionals, on July 8–9, 2026, at the Jio World Convention Centre.The Masterclass will be delivered by RASTA – Center for Road Technology and supported by Construction World and FIRST Construction Council.Designed as an industry-led refresher programme, the Masterclass aims to help engineering and project teams stay updated with the latest advancements in highway construction, pavement technologies, sustainable materials, intelligent compa..

Grand Mercure Mysuru Turns 10; BHVL to Invest Rs 1,000 Crore in Karnataka

Brigade Hotel Ventures Limited (BHVL) has marked the 10th anniversary of its flagship property, Grand Mercure Mysuru, by announcing a major investment plan of around Rs 1,000 crore in Karnataka over the next five years. The company said the investment will be directed towards new hospitality projects as well as modernisation of existing assets, aligning with the evolving demand for experiential tourism.The announcement comes as BHVL reiterated its focus on strengthening Mysuru’s position as a prominent global tourism destination by supporting the local micro-economy and adopting sustainable ..

Ottobock and Celcius Set Up Prosthetics Warehouse in India

Celcius Logistics, a domestic third-party logistics (3PL) company specialising in end-to-end cold-chain solutions, has partnered with Ottobock India, the Indian arm of Germany-based Ottobock, to establish a dedicated prosthetics warehouse and logistics distribution hub in India. As part of the collaboration, a technology-enabled facility has been launched in Thane to streamline storage and nationwide movement of prosthetic and assistive devices.The dedicated warehouse is expected to strengthen the medical supply chain by reducing turnaround time and improving access to prosthetic products acro..